RGN-259 Dry-Eye Study Phase II Results
By: Antonio Chirumbolo SUNY 2013Â RegeneRx Biopharmaceuticals has been working on a treatment for dry eye syndrome, namely its RGN-259. The company has announced completion of treatment and follow up on 69 patients in its Phase II clinical trial. Following statistical analysis, results should be reported in late October. The trial serves to evaluate the …